Meeting
2023 ASCO Annual Meeting
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.
Authors
Elisa Agostinetto
Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium
Elisa Agostinetto , Christos Sotiriou , Michail Ignatiadis , Thayane Antoniolli Crestani , David Venet , Svitlana Tyekucheva , Alexandre Irrthum , Jose A. Seoane , Martine J. Piccart-Gebhart , David A. Cameron , Susan Knox , CRISTINA EMILIA ROTARU , Dario Romagnoli , Gabriele Zoppoli , Philippe Georges Aftimos , Mafalda Oliveira , Meredith M. Regan , Luca Malorni , Matteo Benelli , Florentine Hilbers
Organizations
Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium, Department of Medical Oncology and Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Brussels, Belgium, Department of Medical Oncology and Academic Trials Promoting Team, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B.), Brussels, Belgium, Breast International Group (BIG), Brussels, Belgium, Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Brussels, Belgium, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, Breast International Group, Brussels, Belgium, Cancer Computational Biology Group. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium, Edinburgh University Cancer Centre, Edinburgh, Scotland, United Kingdom, Europa Donna-The European Breast Cancer Coalition, Milan, Italy, Bioinformatic Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy, University of Genova, Genova, Italy, Medical Oncology Department, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B), Brussels, Belgium, Brussels, Belgium, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Dana-Farber Cancer Institute, Boston, MA, Department of Oncology and Translational Research Unit "Sandro Pitigliani", Ospedale di Prato, Azienda USL Toscana Centro, Prato, Italy, Bioinformatics Unit, Hospital of Prato, Prato, Italy, Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands
Research Funding
Other Foundation
AURORA was funded by Breast Cancer Research Foundation (BCRF) as the main funder, Fondation Cancer (Luxembourg), Fondation contre le Cancer (Belgium), NIF Foundation, Barrie and Dena Webb, Candriam, Fondation Futur 21, Sogerim, Think Pink Belgium (SMART Fund), Cognizant Foundation, Eurofins Foundation, Fund Friends of BIG, managed by the King Baudouin Foundation, Pfizer grant for non-drug research, National Lottery (Belgium)
Background: CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is the recommended first line standard of care for patients with estrogen receptor positive (ER+), HER2-negative (HER2-) advanced breast cancer (ABC). However, not all patients derive the same benefit from this treatment. We aimed to identify factors associated with outcome in patients treated with CDK4/6i in a real-world setting. Methods: AURORA (NCT02102165) is an international program aimed at studying ABC by performing multi-omics profiling on paired primary tumors and metastases. Here we present exploratory results from AURORA patients treated with first line CDK4/6i + ET. DNA from primary and/or metastatic lesions and germline DNA was sequenced for 411 cancer-related genes. Endocrine resistance was defined according to the 5th ABC international consensus guidelines at the start of the first line. Local histology assessment of the primary tumor was used. Progression-free survival (PFS) was calculated from the start of CDK4/6i treatment until disease progression or death (whichever occurred first). Results: We analyzed 339 patients treated with CDK4/6i + ET in the first line. PFS differed significantly among the endocrine resistance subgroups (p<0.001). Both TP53 and acquired ESR1 mutations were associated with shorter PFS (hazard ratio [HR] 1.59 [95% CI 1.43-6.73], p=0.004 and 3.10 [95% CI 1.16-2.18], p=0.004 respectively). In a multivariable analysis, acquired ESR1 mutations were significantly associated with worse PFS independently of endocrine resistance status (HR 2.42 [95% CI 1.01-5.79], p=0.048). Mutations in PIK3CA were not associated with outcome (HR 0.84 [95% CI 0.63-1.13], p=0.25). No PFS difference was observed between lobular and ductal tumors (HR 1.07 [95% CI 0.66-1.75], p=0.61). Conclusions: Endocrine resistance status and TP53 and acquired ESR1 mutations were associated with shorter PFS. Factors associated with poor outcome may be used to select patients to test alternative treatment strategies in clinical trials. Clinical trial information: NCT02102165.
| Subgroup | n (%) | PFS events | Median PFS months (95% CI) |
|---|---|---|---|
| All | 339 (100) | 194 | 19.5 (15.9-21.6) |
| Primary resistant | 26 (8) | 20 | 6.6 (3.6-NE) |
| Secondary resistant | 124 (37) | 79 | 14.6 (12.3-19.3) |
| Endocrine sensitive | 93 (27) | 48 | 26.3 (18.6-39.0) |
| Endocrine Naive | 96 (28) | 47 | 27.3 (21.0-40.0) |
| PIK3CA mutated | 137 (40) | 73 | 20.4 (15.6-30.9) |
| TP53 mutated | 79 (23) | 54 | 14.0 (10.8-19.4) |
| acquired ESR1 mutated* | 11 (11) | 8 | 11.7 (3.8-NE) |
| Lobular | 51 (15) | 33 | 19.6 (14.7-26.5) |
*Paired samples only (n=96).
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02102165
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1019)
DOI
10.1200/JCO.2023.41.16_suppl.1019
Abstract #
1019
Poster Bd #
240
Abstract Disclosures
Similar Abstracts
Abstract
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Abstract
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao
Abstract
2023 ASCO Annual Meeting
Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).
First Author: Ann Collier
Abstract
2023 ASCO Annual Meeting
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.
First Author: Timothy A. Yap